Skip to main content
. 2016 Dec 7;40(1):37–47. doi: 10.1007/s40264-016-0474-1

Fig. 5.

Fig. 5

Post-market benefit-risk analysis for both non-active implantable medical devices (NAIMDs) and medicines. RMP risk management plan